Sickle Cell Disease

New England CEPAC

Due to the COVID-19 pandemic, we have decided to indefinitely postpone our upcoming public meeting on therapies for sickle cell disease (originally slated for March 26). Please refer to the sickle cell disease evidence report for our most updated findings.


ICER will assess the comparative clinical effectiveness and value of treatments for sickle cell disease:

  • Crizanlizumab (Novartis) is a P-selectin inhibitor
  • Voxelotor (Global Blood Therapeutics) is an HbS polymerization inhibitor
  • L-gluatmine, an amino acid approved for treatment of sickle cell disease

Date of review: March 2020

For questions, please contact Catherine Koola, Program Manager, at ckoola@icer-review.org.

Associated Meetings

Due to the COVID-19 pandemic, we have decided to indefinitely postpone our upcoming public meeting on therapies for sickle cell disease (originally slated for March 26).


Key Dates

Associated Materials

08/30/2019

08/30/2019 – 09/20/2019

08/30/2019

09/30/2019

11/05/2019

11/21/2019

01/23/2020

01/23/2020

01/23/2020 – 02/20/2020

03/12/2020

03/12/2020

03/12/2020

03/26/2020

03/26/2020

Due to the COVID-19 pandemic, we have decided to indefinitely postpone our upcoming public meeting on therapies for sickle cell disease (originally slated for March 26). Please refer to the sickle cell disease evidence report for our most updated findings.

Evidence Presentation

04/16/2020

Due to the COVID-19 pandemic, we have decided to indefinitely postpone our upcoming public meeting on therapies for sickle cell disease (originally slated for March 26). Please refer to the sickle cell disease evidence report for our most updated findings.

Final Evidence Report and Meeting Summary

04/16/2020

Due to the COVID-19 pandemic, we have decided to indefinitely postpone our upcoming public meeting on therapies for sickle cell disease (originally slated for March 26). Please refer to the sickle cell disease evidence report for our most updated findings.

Report-at-a-Glance